Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism alteration regulating immunotherapy responses to anti-α4β7-integrin in Crohn's disease

• Published in: Gut microbes Vol. 16; no. 1; p. 2310894
• Main Authors: Han, Bing, Tang, Daiyuan, Lv, Xiaodan, Fan, Junhua, Li, Shiquan, Zhu, Hui, Zhang, Jiatong, Xu, Shang, Xu, Xiaofang, Huang, Ziqian, Huang, Zhixi, Lin, Guangfu, Zhan, Lingling, Lv, Xiaoping
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis Group 2024
• Subjects: Animals; Anti-α4β7-integrin; bile acid metabolism; Bile Acids and Salts - therapeutic use; biomarker; Colitis - chemically induced; Colitis - therapy; Crohn Disease - drug therapy; Crohn’s disease; Gastrointestinal Microbiome; Gut microbiota; Immunotherapy; immunotherapy responses; Integrins - genetics; Integrins - therapeutic use; Mice; Multiomics; Gut microbiota; immunotherapy responses; Anti-α4β7-integrin; bile acid metabolism; biomarker; Crohn’s disease
• DOI: 10.1080/19490976.2024.2310894
• ISSN: 1949-0976; 1949-0984

Gut microbiota and related metabolites are both crucial factors that significantly influence how individuals with Crohn's disease respond to immunotherapy. However, little is known about the interplay among gut microbiota, metabolites, Crohn's disease, and the response to anti-α4β7-integrin in current studies. Our research utilized 2,4,6-trinitrobenzene sulfonic acid to induce colitis based on the humanized immune system mouse model and employed a combination of whole-genome shotgun metagenomics and non-targeted metabolomics to investigate immunotherapy responses. Additionally, clinical cases with Crohn's disease initiating anti-α4β7-integrin therapy were evaluated comprehensively. Particularly, 16S-rDNA gene high-throughput sequencing and targeted bile acid metabolomics were conducted at weeks 0, 14, and 54. We found that anti-α4β7-integrin therapy has shown significant potential for mitigating disease phenotypes in remission-achieving colitis mice. Microbial profiles demonstrated that not only microbial composition but also microbially encoded metabolic pathways could predict immunotherapy responses. Metabonomic signatures revealed that bile acid metabolism alteration, especially elevated secondary bile acids, was a determinant of immunotherapy responses. Especially, the remission mice significantly enriched the proportion of the beneficial and genera, which were correlated with increased gastrointestinal levels of BAs involving lithocholic acid and deoxycholic acid. Moreover, most of the omics features observed in colitis mice were replicated in clinical cases. Notably, anti-α4β7 integrin provided sustained therapeutic benefits in clinical remitters during follow-up, and long-lasting remission was linked to persistent changes in the microbial-related bile acids. In conclusion, gut microbiota-mediated bile acid metabolism alteration could play a crucial role in regulating immunotherapy responses to anti-α4β7-integrin in Crohn's disease. Therefore, the identification of prognostic microbial signals facilitates the advancement of targeted probiotics that activate anti-inflammatory bile acid metabolic pathways, thereby improving immunotherapy responses. The integrated multi-omics established in our research provide valuable insights into potential mechanisms that impact treatment responses in complex diseases.